{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:34:41Z","timestamp":1788381281036,"version":"build-2803163510"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I\/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and M2-1), administered to 12\u201323-month-old RSV-seropositive children followed up for 2 years after vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Children were randomized to receive 2 doses of ChAd155-RSV or placebo (at a 1:1 ratio) (days 1 and 31). Doses escalated from 0.5 \u00d7 1010 (low dose [LD]) to 1.5 \u00d7 1010 (medium dose [MD]) to 5 \u00d7 1010 (high dose [HD]) viral particles after safety assessment. Study end points included anti\u2013RSV-A neutralizing antibody (Nab) titers through year 1 and safety through year 2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-two participants were vaccinated, including 11, 14, and 18 in the RSV-LD, RSV-MD, and RSV-HD groups, respectively, and 39 in the placebo groups. Solicited adverse events were similar across groups, except for fever (more frequent with RSV-HD). Most fevers were mild (\u226438.5\u00b0C). No vaccine-related serious adverse events or RSV-related hospitalizations were reported. There was a dose-dependent increase in RSV-A Nab titers in all groups after dose 1, without further increase after dose 2. RSV-A Nab titers remained higher than prevaccination levels at year 1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Three ChAd155-RSV dosages were found to be well tolerated. A dose-dependent immune response was observed after dose 1, with no observed booster effect after dose 2. Further investigation of ChAd155-RSV in RSV-seronegative children is warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02927873.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac481","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T12:49:08Z","timestamp":1670590148000},"page":"1293-1302","source":"Crossref","is-referenced-by-count":24,"title":["Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12\u201323 Months of Age"],"prefix":"10.1093","volume":"227","author":[{"given":"Javier","family":"D\u00edez-Domingo","sequence":"first","affiliation":[{"name":"Vaccine Research Department, FISABIO Public Health , Valencia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Ni\u00f1o Dr Jos\u00e9 Ren\u00e1n Esquivel and Cevaxin Clinical Research Center , Panama City , Panama"},{"name":"National Investigation System, Senacyt , Panama City , Panama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Rodriguez-Weber","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Instituto Nacional de Pediatr\u00eda , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Epalza","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre , Madrid , Spain"},{"name":"Research and Clinical Trials Unit , Madrid , Spain"},{"name":"Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre , Madrid , Spain"},{"name":"RITIP (Traslational Research Network in Pediatric Infectious Diseases), Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Chicago Medical School, Rosalind Franklin University of Medicine and Science , North Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-7743","authenticated-orcid":false,"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University Taoyuan , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hsinchu Mackay Memorial Hospital , Hsinchu City , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[{"name":"Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Cl\u00ednico Universitario de Santiago , Santiago de Compostela , Spain"},{"name":"Genetics, Vaccines, Infectious Diseases and Pediatrics Research Group, Spain, Instituto de Investigaci\u00f3n Sanitaria de Santiago, Universidad de Santiago de Compostela , Galicia , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Baquero-Artigao","sequence":"additional","affiliation":[{"name":"Hospital Universitario Infantil La Paz, Department of Infectious Diseases and Tropical Pediatrics, Spain; CIBERINFEC, Instituto de Salud Carlos III , Madrid , Spain"},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M","family":"Langley","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Iwk Health Centre and Nova Scotia Health Authority, Dalhousie University , Halifax , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 T","family":"Ramos Amador","sequence":"additional","affiliation":[{"name":"Departamento De Salud P\u00fablica Y Materno-infantil, Hospital Universitario Cl\u00ednico San Carlos , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B","family":"Domachowske","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, SUNY Upstate Medical University , Syracuse, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Min","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Taiwan University Hospital , Taipei City , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Chang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mackay Memorial Hospital , Taipei City , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pietro Barilla Children's Hospital, University of Parma, Pediatric Clinic , Parma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moris","sequence":"additional","affiliation":[{"name":"GSK , Rixensart , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi","family":"Lien-Anh Nguyen","sequence":"additional","affiliation":[{"name":"GSK , Wavre , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Nikic","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Woo","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhou","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Dieussaert","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Leach","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez Lopez","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vanhoutte","sequence":"additional","affiliation":[{"name":"GSK , Rixensart , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"2023052916412759500_jiac481-B1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S2213-2600(20)30322-2","article-title":"National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study","volume":"9","author":"Li","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2023052916412759500_jiac481-B2","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","article-title":"Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2023052916412759500_jiac481-B3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"2023052916412759500_jiac481-B4","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023052916412759500_jiac481-B5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"2023052916412759500_jiac481-B6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol Res"},{"key":"2023052916412759500_jiac481-B7","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.4049\/jimmunol.179.8.5415","article-title":"CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"179","author":"Olson","year":"2007","journal-title":"J Immunol"},{"key":"2023052916412759500_jiac481-B8","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol"},{"key":"2023052916412759500_jiac481-B9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/erv.13.15","article-title":"Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials","volume":"12","author":"Capone","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"2023052916412759500_jiac481-B10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3389\/fimmu.2019.01675","article-title":"Biology of infection and disease pathogenesis to guide RSV vaccine development","volume":"10","author":"Boyoglu-Barnum","year":"2019","journal-title":"Front Immunol"},{"key":"2023052916412759500_jiac481-B11","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","article-title":"First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vector-expressing RSV fusion, nucleocapsid, and antitermination viral proteins in healthy adults","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023052916412759500_jiac481-B12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.vaccine.2015.05.093","article-title":"WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23\u201324 March 2015","volume":"34","author":"Modjarrad","year":"2016","journal-title":"Vaccine"},{"key":"2023052916412759500_jiac481-B13","doi-asserted-by":"crossref","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023052916412759500_jiac481-B14","doi-asserted-by":"crossref","first-page":"104867","DOI":"10.1016\/j.micpath.2021.104867","article-title":"Th17\/Treg cell imbalance plays an important role in respiratory syncytial virus infection compromising asthma tolerance in mice","volume":"156","author":"Shi","year":"2021","journal-title":"Microb Pathog"},{"key":"2023052916412759500_jiac481-B15","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what's important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac481\/48441949\/jiac481.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/11\/1293\/50482145\/jiac481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/11\/1293\/50482145\/jiac481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T16:41:51Z","timestamp":1685378511000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/227\/11\/1293\/6885338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2023,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac481","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,12,9]]}}}